261 related articles for article (PubMed ID: 36439173)
1. Targeting matrix metalloproteases: A promising strategy for herbal medicines to treat rheumatoid arthritis.
Li RL; Duan HX; Liang Q; Huang YL; Wang LY; Zhang Q; Wu CJ; Liu SQ; Peng W
Front Immunol; 2022; 13():1046810. PubMed ID: 36439173
[TBL] [Abstract][Full Text] [Related]
2. [Matrix metalloproteinases and cartilage matrix degradation in rheumatoid arthritis].
Yoshihara Y; Yamada H
Clin Calcium; 2007 Apr; 17(4):500-8. PubMed ID: 17404478
[TBL] [Abstract][Full Text] [Related]
3. Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis.
Wang Y; Chen S; Du K; Liang C; Wang S; Owusu Boadi E; Li J; Pang X; He J; Chang YX
J Ethnopharmacol; 2021 Oct; 279():114368. PubMed ID: 34197960
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts.
Migita K; Eguchi K; Kawabe Y; Ichinose Y; Tsukada T; Aoyagi T; Nakamura H; Nagataki S
Immunology; 1996 Dec; 89(4):553-7. PubMed ID: 9014820
[TBL] [Abstract][Full Text] [Related]
5. Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.
Araki Y; Mimura T
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28441353
[TBL] [Abstract][Full Text] [Related]
6. Phytochemicals targeting matrix metalloproteinases regulating tissue degradation in inflammation and rheumatoid arthritis.
Alamgeer ; Hasan UH; Uttra AM; Qasim S; Ikram J; Saleem M; Niazi ZR
Phytomedicine; 2020 Jan; 66():153134. PubMed ID: 31812101
[TBL] [Abstract][Full Text] [Related]
7. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation.
Jackson C; Nguyen M; Arkell J; Sambrook P
Inflamm Res; 2001 Apr; 50(4):183-6. PubMed ID: 11392606
[TBL] [Abstract][Full Text] [Related]
8. Metalloproteinases in Rheumatoid Arthritis: Potential Therapeutic Targets to Improve Current Therapies.
Itoh Y
Prog Mol Biol Transl Sci; 2017; 148():327-338. PubMed ID: 28662826
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis.
Yoshihara Y; Nakamura H; Obata K; Yamada H; Hayakawa T; Fujikawa K; Okada Y
Ann Rheum Dis; 2000 Jun; 59(6):455-61. PubMed ID: 10834863
[TBL] [Abstract][Full Text] [Related]
10. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis.
Konttinen YT; Ainola M; Valleala H; Ma J; Ida H; Mandelin J; Kinne RW; Santavirta S; Sorsa T; López-Otín C; Takagi M
Ann Rheum Dis; 1999 Nov; 58(11):691-7. PubMed ID: 10531073
[TBL] [Abstract][Full Text] [Related]
11. Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis.
Pap T; Shigeyama Y; Kuchen S; Fernihough JK; Simmen B; Gay RE; Billingham M; Gay S
Arthritis Rheum; 2000 Jun; 43(6):1226-32. PubMed ID: 10857781
[TBL] [Abstract][Full Text] [Related]
12. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis.
Ishiguro N; Ito T; Oguchi T; Kojima T; Iwata H; Ionescu M; Poole AR
Arthritis Rheum; 2001 Nov; 44(11):2503-11. PubMed ID: 11710706
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy.
Andreakos E; Smith C; Kiriakidis S; Monaco C; de Martin R; Brennan FM; Paleolog E; Feldmann M; Foxwell BM
Arthritis Rheum; 2003 Jul; 48(7):1901-12. PubMed ID: 12847684
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in different histological variants of rheumatoid synovitis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik B; Skowronski J; Chwiecko J
Rheumatology (Oxford); 2002 Jan; 41(1):78-87. PubMed ID: 11792884
[TBL] [Abstract][Full Text] [Related]
15. [Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the pathogenesis of rheumatoid arthritis].
Fiedorczyk M; Klimiuk PA; Sierakowski S; Kita K
Pol Merkur Lekarski; 2006 Feb; 20(116):228-31. PubMed ID: 16708647
[TBL] [Abstract][Full Text] [Related]
16. Periodontal Disease as a Risk Factor for Rheumatoid Arthritis: A Systematic Review.
Kaur S; White S; Bartold M
JBI Libr Syst Rev; 2012; 10(42 Suppl):1-12. PubMed ID: 27820156
[TBL] [Abstract][Full Text] [Related]
17. Metalloproteases and inhibitors in arthritic diseases.
Martel-Pelletier J; Welsch DJ; Pelletier JP
Best Pract Res Clin Rheumatol; 2001 Dec; 15(5):805-29. PubMed ID: 11812023
[TBL] [Abstract][Full Text] [Related]
18. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory roles of metalloproteinases in rheumatoid arthritis.
Bian Y; Xiang Z; Wang Y; Ren Q; Chen G; Xiang B; Wang J; Zhang C; Pei S; Guo S; Xiao L
Front Pharmacol; 2023; 14():1285455. PubMed ID: 38035026
[TBL] [Abstract][Full Text] [Related]
20. [Cartilage degradation in rheumatoid arthritis].
Ishiguro N
Clin Calcium; 2009 Mar; 19(3):347-54. PubMed ID: 19252244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
